CN114854669A - A method for constructing a cell model of precancerous lesions of esophageal epithelial cells - Google Patents
A method for constructing a cell model of precancerous lesions of esophageal epithelial cells Download PDFInfo
- Publication number
- CN114854669A CN114854669A CN202210590293.8A CN202210590293A CN114854669A CN 114854669 A CN114854669 A CN 114854669A CN 202210590293 A CN202210590293 A CN 202210590293A CN 114854669 A CN114854669 A CN 114854669A
- Authority
- CN
- China
- Prior art keywords
- cell
- afb1
- cells
- well
- heec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000003902 lesion Effects 0.000 title claims abstract description 19
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 18
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 claims abstract description 43
- 229930020125 aflatoxin-B1 Natural products 0.000 claims abstract description 43
- 102400000888 Cholecystokinin-8 Human genes 0.000 claims abstract description 22
- 101800005151 Cholecystokinin-8 Proteins 0.000 claims abstract description 22
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims abstract description 21
- 238000010276 construction Methods 0.000 claims abstract description 16
- 238000000684 flow cytometry Methods 0.000 claims abstract description 16
- 230000022131 cell cycle Effects 0.000 claims abstract description 10
- 230000006907 apoptotic process Effects 0.000 claims abstract description 9
- 230000035899 viability Effects 0.000 claims abstract description 8
- 230000005012 migration Effects 0.000 claims abstract description 6
- 238000013508 migration Methods 0.000 claims abstract description 6
- 101100449517 Arabidopsis thaliana GRH1 gene Proteins 0.000 claims abstract 12
- 101100434479 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AFB1 gene Proteins 0.000 claims abstract 12
- 239000001963 growth medium Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 9
- 208000005374 Poisoning Diseases 0.000 claims description 7
- 231100000572 poisoning Toxicity 0.000 claims description 7
- 230000000607 poisoning effect Effects 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 6
- 230000003833 cell viability Effects 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960005322 streptomycin Drugs 0.000 claims description 3
- 239000003292 glue Substances 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract description 9
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract description 9
- 201000004101 esophageal cancer Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 3
- 238000011160 research Methods 0.000 abstract description 3
- 210000003238 esophagus Anatomy 0.000 abstract description 2
- 230000009456 molecular mechanism Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 239000002115 aflatoxin B1 Substances 0.000 description 31
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000035519 G0 Phase Effects 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 108010060273 Cyclin A2 Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- NGXUJKBJBFLCAR-UHFFFAOYSA-N n-benzyl-n-methylnitrous amide Chemical compound O=NN(C)CC1=CC=CC=C1 NGXUJKBJBFLCAR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及细胞模型构建方法技术领域,尤其是一种食管上皮细胞癌前病变细胞模型的构建方法,现提出如下方案,其包括使用1μmol/LAFB1溶液长期连续干预HEEC至第30代,采用CCK8法来检测AFB1染毒不同代数的HEEC活力的影响,采用流式细胞仪检测不同代数细胞的细胞凋亡、细胞周期,采用Transwell法检测染毒30代细胞的侵袭、迁移能力。本发明进一步探索AFB1在食管癌发生过程的相关分子机制,为食管癌的病因学研究奠定基础,为防止食品中AFB1对食管的毒性提供一定的理论依据。
The invention relates to the technical field of cell model construction methods, in particular to a construction method for a cell model of precancerous lesions of esophageal epithelial cells. The following scheme is now proposed, which includes using 1 μmol/LAFB1 solution to continuously intervene HEEC to the 30th generation for a long time, and adopting the CCK8 method. To detect the effect of AFB1 exposure on HEEC viability of different passages, flow cytometry was used to detect cell apoptosis and cell cycle of different passages, and Transwell method was used to detect the invasion and migration ability of 30 passages of exposed cells. The present invention further explores the relevant molecular mechanism of AFB1 in the occurrence process of esophageal cancer, lays a foundation for the etiology research of esophageal cancer, and provides a certain theoretical basis for preventing the toxicity of AFB1 in food to the esophagus.
Description
技术领域technical field
本发明涉及细胞模型构建方法领域,尤其是一种食管上皮细胞癌前病变细胞模型的构建方法。The invention relates to the field of cell model construction methods, in particular to a construction method of an esophageal epithelial cell precancerous lesion cell model.
背景技术Background technique
国际癌症研究机构报告显示,全球食管癌发病率在所有癌症中排名第七,总死亡率在所有癌症中排名第六,环境、饮食习惯、生活方式在食管癌的发生过程中起着重要作用,其中,霉菌毒素感染被认为是中国食管癌高发区居民食管癌发生的重要危险因素之一。黄曲霉毒素B1是食物中最常见的也是毒性最大的霉菌毒素,且在1993年AF B1被IARC定义为I类致癌物。一项病例对照研究表明,黄曲霉毒素B1的高暴露可能是中国淮安(食管癌高发区)食管癌前病变的重要危险因素。近年来,有关食管癌前病变细胞模型的建立方法极少见到,大多使用甲基苄基亚硝胺诱导建立食管癌前病变动物模型,为此,本发明提出了一种食管上皮细胞癌前病变细胞模型的构建方法。According to the report of the International Agency for Research on Cancer, the global incidence of esophageal cancer ranks seventh among all cancers, and the total mortality ranks sixth among all cancers. Environment, dietary habits, and lifestyle play an important role in the occurrence of esophageal cancer. Among them, mycotoxin infection is considered to be one of the important risk factors for the occurrence of esophageal cancer in residents of high-incidence areas of esophageal cancer in China. Aflatoxin B1 is the most common and the most toxic mycotoxin in food, and AF B1 was defined as a class I carcinogen by IARC in 1993. A case-control study suggests that high exposure to aflatoxin B1 may be an important risk factor for esophageal precancerous lesions in Huai'an, China, an area with a high incidence of esophageal cancer. In recent years, the establishment method of esophageal precancerous lesion cell model is rarely seen, and most of them use methylbenzylnitrosamine to induce the establishment of esophageal precancerous lesion animal model. Therefore, the present invention proposes a precancerous esophageal epithelial cell Methods of constructing diseased cell models.
发明内容SUMMARY OF THE INVENTION
为解决现有技术中的问题,本发明提出了一种食管上皮细胞癌前病变细胞模型的构建方法。In order to solve the problems in the prior art, the present invention provides a method for constructing an esophageal epithelial cell precancerous lesion cell model.
为了实现上述目的,本发明采用了如下技术方案:In order to achieve the above object, the present invention adopts the following technical solutions:
一种食管上皮细胞癌前病变细胞模型的构建方法,包括如下步骤:A method for constructing an esophageal epithelial cell precancerous lesion cell model, comprising the following steps:
步骤一,培养HEEC;
步骤二,染毒处理:将AFB1粉末溶于DMSO中得到10mmol/L的混合液,再加入完全培养液稀释混合液得到1μmol/LAFB1染毒液;Step 2, poisoning treatment: dissolving the AFB1 powder in DMSO to obtain a 10 mmol/L mixed solution, and then adding the complete culture solution to dilute the mixed solution to obtain a 1 μmol/LAFB1 poisoning solution;
将所述HEEC以40%密度接种25cm2培养瓶中,培养过夜,待HEEC贴壁恢复形态后进行AFB1处理,传代,此为AFB1处理第一代细胞,待细胞恢复形态贴壁过夜后,重复进行AFB1处理,重复培养30代,其中每处理5代,对相应细胞进行液氮冻存,所述AFB1处理为在HEEC中加入1μmol/LAFB1染毒液培养48-72小时。The HEECs were inoculated into a 25cm 2 culture flask at a density of 40% and cultured overnight. After the HEECs adhered to the walls and recovered their shape, they were treated with AFB1 and passaged. This was the first generation of cells treated with AFB1. AFB1 treatment was performed, and the culture was repeated for 30 generations, wherein the corresponding cells were cryopreserved in liquid nitrogen for each treatment for 5 generations. The AFB1 treatment was performed by adding 1 μmol/LAFB1 venom solution to HEECs and cultured for 48-72 hours.
进一步地,所述培养HEEC的步骤为:将HEEC置于完全培养液中并置于5%CO2、37℃的培养箱中,所述完全培养液包括高糖DMEM培养液、FBS和双抗,高糖DMEM培养液:FBS:双抗的体积比为10:1:0.1,双抗为100U/ml的链霉素和100U/ml的青霉素。Further, the step of culturing HEECs is: placing HEECs in a complete culture medium and in an incubator with 5% CO 2 and 37° C. The complete culture medium includes high-glucose DMEM medium, FBS and double antibody , the volume ratio of high glucose DMEM medium: FBS: double antibody is 10: 1: 0.1, and the double antibody is 100U/ml streptomycin and 100U/ml penicillin.
进一步地,所述构建方法包括采用CCK8法检测染毒处理后的HEEC活力。Further, the construction method includes using the CCK8 method to detect the HEEC activity after the exposure treatment.
进一步地,检测染毒处理后的HEEC活力的步骤包括如下:将HEEC以6×103个/孔密度接种于96孔板中,每孔体积100μL,置于37℃、5%CO2培养箱内培养;24h后,板内分别加入100μL含0、0.01、0.1、1、10、100、1000μmol/L的AFB1培养液,每组5个复孔,并设置空白孔染毒24h;后弃去培养液,换成100μL完全培养液,随即每干预孔贴壁加入10μL CCK8溶液,培养箱内孵育1.5h,置于酶标仪CCK8模式下测定各孔OD值,记录结果取平均值。Further, the steps of detecting the HEEC viability after exposure treatment include the following: inoculating HEECs at a density of 6×10 3 /well in a 96-well plate, with a volume of 100 μL per well, and placing them in a 37°C, 5% CO 2 incubator After 24 hours, 100 μL of AFB1 medium containing 0, 0.01, 0.1, 1, 10, 100, and 1000 μmol/L were added to the plate, 5 replicate wells in each group, and blank wells were set to infect them for 24 hours; then discarded The culture medium was replaced with 100 μL of complete culture medium, and then 10 μL of CCK8 solution was added to the wall of each intervention well, incubated in the incubator for 1.5 h, placed in the CCK8 mode of the microplate reader to measure the OD value of each well, and the recorded results were averaged.
进一步地,检测染毒处理后的HEEC活力的步骤包括检测AFB1干预后每隔5代细胞活力:将含AFB1培养液染毒的第5、10、15、20、25、30代的细胞以6×103个/孔密度接种于96孔板中,每孔体积100μL,置于37℃、5%CO2培养箱内培养48h后,弃去培养液,换成100μL完全培养液,随即每干预孔贴壁加入10μL CCK8溶液,小心避免产生气泡,培养箱内孵育1.5h,置于酶标仪CCK8模式下测定各孔OD值,记录结果取平均值。Further, the step of detecting the viability of HEECs after exposure treatment includes detecting the viability of cells at every 5th passage after AFB1 intervention: cells at
进一步地,所述构建方法包括计算细胞存活率:细胞存活率=(试验组OD-空白组OD)/(对照组OD-空白组OD)×100%。Further, the construction method includes calculating the cell survival rate: cell survival rate=(OD of test group-OD of blank group)/(OD of control group-OD of blank group)×100%.
进一步地,所述构建方法包括采用流式细胞术检测细胞周期。Further, the construction method includes using flow cytometry to detect cell cycle.
进一步地,所述构建方法包括采用流式细胞仪检测细胞凋亡、采用Transwell法检测细胞的迁移能力、采用Transwell法检测细胞的侵袭能力。Further, the construction method includes detecting cell apoptosis by flow cytometry, detecting cell migration ability by Transwell method, and detecting cell invasion ability by Transwell method.
进一步地,采用Transwell法检测细胞的侵袭能力包括:用无FBS的培养液稀释Matrigel胶,稀释比例为1:8;小室每孔加50μL稀释液,4℃冷藏静置,至第二天实验使用;将未染毒的HEEC、AFB1染毒30代的细胞用胰酶消化后离心,用不含FBS的培养液调整各组细胞密度为3×105个/孔,在铺好胶的上室加入200μL细胞悬液,下室加入600μL含50%FBS的培养液。Further, using the Transwell method to detect the invasive ability of cells includes: diluting Matrigel gel with FBS-free culture medium at a dilution ratio of 1:8; adding 50 μL of diluent to each well of the chamber, refrigerating at 4°C and standing until the next day for experimental use ; Uninfected HEEC and AFB1-infected cells for 30 passages were digested with trypsin and centrifuged, and the cell density of each group was adjusted to 3×10 5 cells/well with culture medium without FBS. 200 μL of cell suspension was added, and 600 μL of culture medium containing 50% FBS was added to the lower chamber.
本发明的有益效果:Beneficial effects of the present invention:
本发明公开了一种食管正常上皮细胞(HEEC)经黄曲霉毒素B1(AFB1)长期干预为食管癌前病变细胞模型的方法,建立方法为:使用1μmol/LAFB1溶液长期连续干预HEEC至第30代,采用CCK8法来检测AFB1染毒不同代数的HEEC活力的影响,采用流式细胞仪检测不同代数细胞的细胞凋亡、细胞周期,采用Transwell法检测染毒30代细胞的侵袭、迁移能力,采用Western blot法检测EMT相关蛋白(E-cadherin、N-cadherin)、细胞周期相关蛋白(cyclin A2、cyclin D1及CDK2)的表达。本发明进一步探索AFB1在食管癌发生过程的相关分子机制,为食管癌的病因学研究奠定基础,为防止食品中AFB1对食管的毒性提供一定的理论依据。The invention discloses a method for long-term intervention of normal esophageal epithelial cells (HEEC) by aflatoxin B1 (AFB1) into an esophageal precancerous lesion cell model. , CCK8 method was used to detect the effect of AFB1 exposure on HEEC viability of different passages, flow cytometry was used to detect cell apoptosis and cell cycle of different passages, and Transwell method was used to detect the invasion and migration ability of 30 passages of exposed cells. Western blot was used to detect the expressions of EMT-related proteins (E-cadherin, N-cadherin) and cell cycle-related proteins (cyclin A2, cyclin D1 and CDK2). The present invention further explores the relevant molecular mechanism of AFB1 in the occurrence process of esophageal cancer, lays a foundation for the etiology research of esophageal cancer, and provides a certain theoretical basis for preventing the toxicity of AFB1 in food to the esophagus.
附图说明Description of drawings
图1是本发明采用CCK8法检测HEEC的活力情况的关系示意图;Fig. 1 is that the present invention adopts CCK8 method to detect the relationship schematic diagram of the vitality situation of HEEC;
图2是本发明采用CCK8法检测HEEC的增殖情况的关系示意图;Fig. 2 is the relational schematic diagram that the present invention adopts CCK8 method to detect the proliferation situation of HEEC;
图3是本发明采用流式细胞术检测HEEC的细胞周期情况的关系示意图;3 is a schematic diagram of the relationship between the present invention using flow cytometry to detect the cell cycle of HEEC;
图4是本发明采用流式细胞术检测HEEC的细胞凋亡情况的关系示意图;4 is a schematic diagram of the relationship between the present invention using flow cytometry to detect the apoptosis of HEEC;
图5是本发明采用Transwell法检测HEEC迁移能力的关系示意图;Fig. 5 is the relational schematic diagram that the present invention adopts Transwell method to detect the migration ability of HEEC;
图6是本发明采用Transwell法检测HEEC侵袭能力的关系示意图;Fig. 6 is the relational schematic diagram that the present invention adopts Transwell method to detect HEEC invasion ability;
图7是本发明整体流程示意图。FIG. 7 is a schematic diagram of the overall flow of the present invention.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments.
本发明中各缩写指代的含义为:HEEC:食管正常上皮细胞,AFB1:黄曲霉毒素B1,PBS:磷酸盐缓冲溶液,DMSO:二甲基亚砜,DMEM:dulbecco's modified eagle medium;The meanings of the abbreviations in the present invention are: HEEC: normal esophageal epithelial cells, AFB1: aflatoxin B1, PBS: phosphate buffered solution, DMSO: dimethyl sulfoxide, DMEM: dulbecco's modified eagle medium;
一种食管上皮细胞癌前病变细胞模型的构建方法,如图7所示,用AFB1长期连续干预HEEC,具体方法:A method for constructing an esophageal epithelial cell precancerous lesion cell model, as shown in Figure 7, uses AFB1 to continuously intervene HEEC for a long time. The specific method is as follows:
(1)细胞培养(1) Cell culture
用高糖DMEM培养液、FBS(胎牛血清)、双抗(100U/ml链霉素、100U/ml青霉素)配制细胞培养液,三者比例为10:1:0.1,置于5%CO2、37℃培养箱中,用配好的完全培养液培养HEEC,待细胞密度达80-90%,即可进行传代、实验或冻存等操作。Prepare cell culture medium with high glucose DMEM medium, FBS (fetal bovine serum), and double antibody (100U/ml streptomycin, 100U/ml penicillin) in a ratio of 10:1:0.1, placed in 5% CO2 , in a 37°C incubator, culture HEEC with the prepared complete culture medium, and when the cell density reaches 80-90%, operations such as passage, experiment or cryopreservation can be performed.
(2)染毒处理(2) Poisoning treatment
①配置AFB1染毒液母液:将AFB1粉末溶于DMSO,浓度为10mmol/L,若长期使用,可放置于4℃冰箱内。①Configure AFB1 poisoning liquid mother solution: Dissolve AFB1 powder in DMSO, the concentration is 10mmol/L, if it is used for a long time, it can be placed in a 4°C refrigerator.
②长期AFB1染毒处理:根据前期CCK8细胞增殖实验结果,确定AFB1染毒浓度为1μmol/L,诱导细胞恶性转化。用完全培养液将其稀释成1μmol/L,现配现用。细胞以约40%密度接种25cm2培养瓶,培养过夜,待细胞贴壁恢复形态后,用含1μmol/L AFB1的DMEM培养液培养48-72小时后传代,此为AFB1处理第一代细胞,待细胞恢复形态贴壁过夜后,重复进行相同的AFB1处理,如此重复培养30代。其中每处理5代,对相应细胞进行液氮冻存。②Long-term AFB1 exposure treatment: According to the results of the previous CCK8 cell proliferation experiments, it was determined that the AFB1 exposure concentration was 1 μmol/L to induce malignant transformation of cells. It was diluted to 1 μmol/L with complete culture medium, and it was prepared and used now. The cells were inoculated into a 25cm 2 culture flask at a density of about 40%, and cultured overnight. After the cells adhered to the wall and recovered their shape, they were cultured in DMEM medium containing 1 μmol/L AFB1 for 48-72 hours and then passaged. This is the first generation of cells treated with AFB1. After the cells recovered their form and adhered overnight, the same AFB1 treatment was repeated, and the culture was repeated for 30 generations. The corresponding cells were cryopreserved in liquid nitrogen for each treatment for 5 passages.
可用CCK8法检测该细胞的活力及增殖情况。The cell viability and proliferation can be detected by CCK8 method.
(1)测AFB1干预后HEEC活力(1) Measure HEEC activity after AFB1 intervention
将HEEC以6×103个/孔密度接种于96孔板中,每孔体积100μL,置于37℃、5%CO2培养箱内培养。24h后,板内分别加入100μL含0、0.01、0.1、1、10、100、1000μmol/L的AFB1培养液,每组5个复孔,并设置空白孔(不含细胞,只含培养液,为去除背景值)染毒24h;后弃去培养液,换成100μL完全培养液,随即每干预孔贴壁加入10μL CCK8溶液,小心避免产生气泡,培养箱内孵育1.5h,置于酶标仪CCK8模式下测定各孔OD值,记录结果取平均值。HEECs were seeded in a 96-well plate at a density of 6×10 3 cells/well, with a volume of 100 μL per well, and cultured in a 37° C., 5% CO 2 incubator. After 24 hours, 100 μL of AFB1 medium containing 0, 0.01, 0.1, 1, 10, 100, and 1000 μmol/L were added to the plate, 5 replicate wells in each group, and blank wells (without cells, only with culture medium, In order to remove the background value) exposure for 24 hours; then discard the culture medium and replace it with 100 μL of complete culture medium, then add 10 μL of CCK8 solution to the wall of each intervention well, be careful to avoid bubbles, incubate in the incubator for 1.5 hours, and place it on a microplate reader The OD value of each well was measured in CCK8 mode, and the results were recorded as the average value.
按上述操作步骤重复进行3次实验。计算细胞存活率:细胞存活率=(试验组OD-空白组OD)/(对照组OD-空白组OD)×100%。Repeat the above steps for 3 times. Calculate the cell viability: cell viability=(OD of test group-OD of blank group)/(OD of control group-OD of blank group)×100%.
(2)测AFB1干预后每隔5代细胞活力(2) Measure cell viability every 5 passages after AFB1 intervention
将含AFB1培养液染毒的第5、10、15、20、25、30代的细胞以6×103个/孔密度接种于96孔板中,每孔体积100μL,置于37℃、5%CO2培养箱内培养48h后,弃去培养液,换成100μL完全培养液,随即每干预孔贴壁加入10μL CCK8溶液,小心避免产生气泡,培养箱内孵育1.5h,置于酶标仪CCK8模式下测定各孔OD值,记录结果取平均值。Cells at
按上述操作步骤重复进行3次实验。计算细胞增殖率:细胞增殖率=(试验组OD-空白组OD)-(对照组OD-空白组OD)/(对照组OD-空白组OD)×100%。Repeat the above steps for 3 times. Calculate the cell proliferation rate: cell proliferation rate=(OD of test group-OD of blank group)-(OD of control group-OD of blank group)/(OD of control group-OD of blank group)×100%.
采用流式细胞术检测细胞周期;Cell cycle detection by flow cytometry;
每组细胞设置三个平行样,将含AFB1培养液染毒0、5、10、15、20、25、30代的细胞种于25cm2培养瓶中,内含3mL培养液,置于37℃、5%CO2饱和湿度培养箱内培养。待细胞贴壁生长48h后,收集各组细胞进行流式检测。用PBS清洗2次,随即加入1ml含0.25%的EDTA胰酶消化细胞,待细胞全部皱缩变圆并有少量飘起后终止消化,转移至15mL离心管,1000rpm离心5min,再用PBS洗两遍后,1000rpm离心5min,调整细胞密度至1×106个,并转移至1.5mL EP管,逐滴加入500μL的70%冰乙醇(提前配制并置于冰箱4℃预冷)。将各组EP管置于冰箱4℃过夜,第二天离心弃去冰乙醇,用PBS洗涤1次离心弃去,随即放入500μL提前配置好的染液(Rnase酶:PI=1:9),轻柔吹打混匀,避光放置30min后,吸取单细胞悬液,过300目筛后,上流式细胞仪检测。Three parallel samples were set for each group of cells, and the cells containing AFB1 culture medium were infected at
采用流式细胞仪检测细胞凋亡;Cell apoptosis was detected by flow cytometry;
每组细胞设置五个平行样,将含AFB1培养液染毒第0、5、10、15、20、25、30代的细胞种于25cm2培养瓶中,内含3ml培养液,置于37℃、5%CO2饱和湿度培养箱内培养。待细胞贴壁,生长48h后,收集各组细胞进行流式检测。收集各组培养液,用PBS洗涤细胞并收集,加入1ml无EDTA的胰酶消化细胞,待细胞全部皱缩变圆并有少量飘起后终止消化,1200rpm离心5min后,再用PBS清洗两遍后离心,随后弃掉上清液,加入适量体积的Binding buffer,保证细胞密度为5×105个,轻柔吹打。后取100-200μL单细胞悬液加5μLAnnexinV-FITC和5μLPI,避光孵育20min后,上流式细胞仪检测。Five parallel samples were set for each group of cells, and the cells at
采用Transwell法检测细胞的迁移能力;The migration ability of cells was detected by Transwell method;
消化离心并收集未染毒的HEEC、AFB1染毒30代的细胞。采用PBS重悬细胞,再次离心后加入无FBS培养液制成单细胞悬液,调整各组细胞密度为5×104个/孔,上室加入200μL细胞悬液,下室加入含20%FBS的600μL培养液,培养24h。培养结束后,用棉签轻柔擦拭处理小室内残余细胞,下室加入600μL甲醇用于固定小室,15min后吸去固定液,加入600μL结晶紫染色液染色15min,随后PBS清洗1-2次,避光风干,在倒置显微镜下观察,每个样本随机选取5个视野拍照,对迁移个数进行计数。Digest and centrifuge and collect uninfected HEEC, AFB1-infected cells for 30 passages. The cells were resuspended in PBS, centrifuged again, and FBS-free culture medium was added to make a single cell suspension. The cell density of each group was adjusted to 5×10 4 cells/well. 600 μL of culture medium was incubated for 24 h. After the incubation, the residual cells in the chamber were gently wiped with a cotton swab, and 600 μL of methanol was added to the lower chamber to fix the chamber. After 15 minutes, the fixative was aspirated, and 600 μL of crystal violet staining solution was added for staining for 15 minutes. Air-dried, observed under an inverted microscope, and 5 fields of view were randomly selected for each sample to take pictures, and the number of migration was counted.
采用Transwell法检测细胞的侵袭能力;The invasive ability of cells was detected by Transwell method;
用无FBS的培养液稀释Matrigel胶,稀释比例为1:8。小室每孔加50μL稀释液,4℃冷藏静置,至第二天实验使用。将未染毒的HEEC、AFB1染毒30代的细胞用胰酶消化后离心,用不含FBS的培养液调整各组细胞密度为3×105个/孔,在铺好胶的上室加入200μL细胞悬液,下室加入600μL含50%FBS的培养液。培养24h后,后续步骤同5。Dilute Matrigel gel with FBS-free medium at a dilution ratio of 1:8. Add 50 μL of diluent to each well of the chamber, refrigerate it at 4°C, and use it until the next day. The uninfected HEEC and AFB1-infected cells for 30 passages were digested with trypsin and centrifuged. The cell density of each group was adjusted to 3×10 5 cells/well with culture medium without FBS, and added to the upper chamber where the gel was laid. 200 μL of cell suspension, 600 μL of culture medium containing 50% FBS was added to the lower chamber. After culturing for 24h, the following steps are the same as 5.
实施例1:使用1mol/LAFB1溶液长期连续干预HEEC至第20代,采用CCK8法来检测HEEC的增殖率为14.31±6.20%,采用流式细胞仪检测HEEC的细胞周期中G0/G1期占比56.78±0.89%,S期占比33.60±0.93%,采用流式细胞仪检测HEEC的细胞凋亡率为18.63±0.36%。Example 1: Using 1mol/LAFB1 solution to continuously intervene HEECs for a long time to the 20th passage, using the CCK8 method to detect the proliferation rate of HEECs at 14.31±6.20%, and using flow cytometry to detect the proportion of G0/G1 phase in the cell cycle of HEECs 56.78±0.89%, S phase accounted for 33.60±0.93%, and the apoptosis rate of HEEC detected by flow cytometry was 18.63±0.36%.
实施例2:使用1mol/LAFB1溶液长期连续干预HEEC至第30代,采用CCK8法来检测HEEC的增殖率为45.79±1.12%,采用流式细胞仪检测HEEC的细胞周期中G0/G1期占比47.44±0.92,S期占比43.69±0.58%,采用流式细胞仪检测HEEC的细胞凋亡率为9.17±0.60%。Example 2: Using 1mol/LAFB1 solution to continuously intervene HEECs for a long time to the 30th passage, using the CCK8 method to detect the proliferation rate of HEECs of 45.79±1.12%, and using flow cytometry to detect the proportion of G0/G1 phase in the cell cycle of HEECs 47.44±0.92, the proportion of S phase was 43.69±0.58%, and the apoptosis rate of HEEC detected by flow cytometry was 9.17±0.60%.
结果发现,使用1mol/LAFB1溶液长期连续干预HEEC至第30代,细胞的增殖能力升高,细胞周期从G0/G1期向S期转化,细胞凋亡减少。The results showed that the long-term continuous intervention of HEEC with 1mol/LAFB1 solution to the 30th passage increased the proliferation ability of the cells, transformed the cell cycle from the G0/G1 phase to the S phase, and decreased cell apoptosis.
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。The above description is only a preferred embodiment of the present invention, but the protection scope of the present invention is not limited to this. The equivalent replacement or change of the inventive concept thereof shall be included within the protection scope of the present invention.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210590293.8A CN114854669A (en) | 2022-05-26 | 2022-05-26 | A method for constructing a cell model of precancerous lesions of esophageal epithelial cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210590293.8A CN114854669A (en) | 2022-05-26 | 2022-05-26 | A method for constructing a cell model of precancerous lesions of esophageal epithelial cells |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114854669A true CN114854669A (en) | 2022-08-05 |
Family
ID=82640981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210590293.8A Withdrawn CN114854669A (en) | 2022-05-26 | 2022-05-26 | A method for constructing a cell model of precancerous lesions of esophageal epithelial cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114854669A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106110336A (en) * | 2016-08-12 | 2016-11-16 | 郑州大学 | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode |
CN108018258A (en) * | 2016-11-04 | 2018-05-11 | 江苏齐氏生物科技有限公司 | A kind of isolation and culture method of primary people's esophageal epithelial cell |
CN109295156A (en) * | 2018-09-17 | 2019-02-01 | 国家食品安全风险评估中心 | Chemicals induce the method for building up of the vitro detection model of human esophagus cancer |
-
2022
- 2022-05-26 CN CN202210590293.8A patent/CN114854669A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106110336A (en) * | 2016-08-12 | 2016-11-16 | 郑州大学 | A kind of construction method of esophageal carcinoma chemoprophylaxis research mode |
CN108018258A (en) * | 2016-11-04 | 2018-05-11 | 江苏齐氏生物科技有限公司 | A kind of isolation and culture method of primary people's esophageal epithelial cell |
CN109295156A (en) * | 2018-09-17 | 2019-02-01 | 国家食品安全风险评估中心 | Chemicals induce the method for building up of the vitro detection model of human esophagus cancer |
Non-Patent Citations (3)
Title |
---|
付凌萌等: "木犀草素与叶酸对黄曲霉毒素B_1致食管上皮细胞毒性及MTHFR基因高甲基化的影响", 《中国优秀硕士论文库医药卫生科技辑》 * |
徐漪等: "DNMT1高表达在MNNG诱导哈萨克族食管上皮细胞恶性转化中的作用", 《癌变.畸变.突变》 * |
马月等: "HPV联合MNNG对Het-1A细胞恶性转化的影响", 《癌变.畸变.突变》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102604889B (en) | HEK (human embryonic kidney) 293 cell line applicable to serum-free culture and application thereof | |
CN101696396A (en) | Construction method and use of model of hepatitis B virus infection in vivo | |
CN107084957B (en) | Method for detecting content of active oxygen in cells | |
CN112553289A (en) | Method for evaluating effectiveness of CAR-T cells | |
CN111363721B (en) | Docetaxel-induced established luminal breast cancer multidrug-resistant cell strain and construction method and application thereof | |
CN112048477B (en) | Establishment method of artificial respiratory tract epithelial model infected by EBV virus | |
CN102094064A (en) | Novel method for testing efficacy of pseudorabies live vaccine | |
CN114854669A (en) | A method for constructing a cell model of precancerous lesions of esophageal epithelial cells | |
CN105062979A (en) | Method for cultivating hepatitis e virus | |
CN106498021A (en) | A kind of detection mouth affects method containing tobacco product to cellular inflammation effector secretory volume | |
CN117143806B (en) | Cell line of garrupa fries, construction method and application thereof | |
CN102590507A (en) | Quick detection method for exogenous avian leukosis virus in DF1 cell culture | |
CN114874989B (en) | A method for capturing circulating tumor cells | |
CN102517255B (en) | Stably-copied cell line containing hepatitis B viruses, preparation method and application | |
CN103756953A (en) | Establishment of ischemia reperfusion injury model of in vitro myocardial cells of SD (Sprague Dawley) rat | |
CN115369089A (en) | Two CDK4/6 inhibitor-resistant strains of ER-positive HER-2-negative breast cancer and their construction methods and uses | |
AU2022275422A1 (en) | Compositions and methods comprising co-culture of hepatocytes | |
CN113341155A (en) | Immunofluorescence method for detecting IgM antibody infected by fever with thrombocytopenia syndrome virus and detection kit thereof | |
CN101693887A (en) | Fast cultivation and identification method of high throughput virus and applications thereof | |
CN109929804B (en) | Human ovarian cancer cell line and preparation method and application thereof | |
CN116004536B (en) | Human esophageal cancer hydrochloric acid An Luoti Nib drug-resistant cell strain, construction method and application thereof | |
CN106645747B (en) | A method for detecting the effect of total particulate matter in smoke on cellular inflammatory effectors | |
CN119144689A (en) | Drug toxicity detection method based on kidney organoids | |
CN119464185A (en) | Pathological pulmonary fibrosis model and its construction method and use | |
CN110760475A (en) | A method for separating and culturing chicken muscle satellite cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220805 |
|
WW01 | Invention patent application withdrawn after publication |